Literature DB >> 6477846

Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs.

B Krauer, P Dayer, R Anner.   

Abstract

The concentration of the two principal drug-binding proteins, albumin and alpha 1-acid glycoprotein, were measured in 44 paired fetal and maternal serum samples obtained at between 12 and 41 weeks gestation. Maternal serum albumin concentrations ranged between 25 and 35 g/l during this period. Fetal serum albumin was much lower in early gestation, ranging from 7.5 to 16 g/l at 12-15 weeks. With advancing age there was a linear increase so that at 30 weeks the fetal and the maternal serum albumin concentrations were in the same range and after 35 weeks the fetal concentrations exceeded the maternal by some 20%. Thus, the mean fetal/maternal serum concentration ratio of albumin increases from early pregnancy to term: 0.38 at 12-15 weeks; 0.66 at 16-25 weeks; 0.97 at 26-35 weeks; and 1.2 at greater than 35 weeks gestation. Maternal serum alpha 1-acid glycoprotein concentrations were scattered widely between 0.38 and 1.05 g/l. With the technique used fetal serum concentrations were hardly detectable before 16 weeks. Thereafter they increased at a constant rate, but never attained the maternal values. Near term a fetal/maternal serum concentration ratio of 0.37 was reached. These changes in protein concentrations may have important pharmacological implications.

Mesh:

Substances:

Year:  1984        PMID: 6477846     DOI: 10.1111/j.1471-0528.1984.tb03700.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  33 in total

1.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

Review 2.  Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy.

Authors:  André Dallmann; Ibrahim Ince; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

Review 3.  The treatment of hypertension in pregnancy. Clinical pharmacokinetic considerations.

Authors:  C Knott
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

4.  Implications of gender and pregnancy for antiretroviral drug dosing.

Authors:  Brookie M Best; Edmund V Capparelli
Journal:  Curr Opin HIV AIDS       Date:  2008-05       Impact factor: 4.283

Review 5.  Therapeutic drug monitoring in pregnancy: rationale and current status.

Authors:  C Knott; F Reynolds
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

6.  Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women.

Authors:  Rodrigo Metzker Pereira Ribeiro; Fernanda de Lima Moreira; Elaine Christine Dantas Moisés; Ricardo Carvalho Cavalli; Silvana Maria Quintana; Vera Lucia Lanchote; Geraldo Duarte
Journal:  Br J Clin Pharmacol       Date:  2018-08-02       Impact factor: 4.335

7.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

8.  Lopinavir exposure with an increased dose during pregnancy.

Authors:  Mark Mirochnick; Brookie M Best; Alice M Stek; Edmund Capparelli; Chengcheng Hu; Sandra K Burchett; Diane T Holland; Elizabeth Smith; Sreedhar Gaddipati; Jennifer S Read
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

9.  Tacrolimus placental transfer at delivery and neonatal exposure through breast milk.

Authors:  Songmao Zheng; Thomas R Easterling; Karen Hays; Jason G Umans; Menachem Miodovnik; Shannon Clark; Justina C Calamia; Kenneth E Thummel; Danny D Shen; Connie L Davis; Mary F Hebert
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

10.  A clinical trial of a slow-release formulation of acetylsalicylic acid in patients at risk for preeclampsia.

Authors:  J Shen; S Wanwimolruk; P D Wilson; R J Seddon; M S Roberts
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.